glp 1 crohn's Ozempic and Disease: Could GLP-1s Help? Frontiers | GLP-1 and GLP-2

VRA, BSC, RAG, JG, NMM and SER were the writing group members for ADA

If you want a choice, this may feel limited

Semaglutide (Wegovy) and Kidney Protection Clinical evidence from the landmark FLOW trial, published in May 2024, revealed that Semaglutide 1.0 mg reduced the risk of major kidney disease events by 24% in participants with type 2 diabetes and CKD

This removes the conflict of interest inherent in self-testing

Incidence of Symptomatic Gallstone Disease in Bariatric Patients Undergoing Sleeve Gastrectomy, and the Dilemma of Prophylactic Cholecystectomy: A Single-Center Retrospective Study

Problems with the concept of gut microbiota dysbiosis